US 12,692,294 B2Granted

Engineered NRG-1 variants with improved selectivity toward ErbB4 but not against ErbB3

AssigneeAmgen Inc.

InventorsDarren L. Bates, Zhi Liu, TaeWeon Lee, Mark L. Michaels, Zhulun Wang

Life of this patent

Estimating the term…

Abstract

The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

Claims4

Dependent claims

A neuregulin variant is represented by an amino acid sequence of SEQ ID NO:

117 or 126.

Dependencies are inferred from the claim text.

Facts

Application: 17/836,425Filed 9 Jun 2022 · us provisional application
Priority: 10 Jun 2021
Published: US 2022/0402985 A122 Dec 2022
Granted: 28 Jul 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

C07K 14/485
Growth factors; Growth regulators: epidermal growth factor [EGF], i.e. urogastrone
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…
A61K 38/00
Medicinal preparations containing peptides
C07K
Peptides

Family

Application63/209,248Us provisional application · filed 10 Jun 2021
US 2022/0402985 A1Pre-grant publication · published 22 Dec 2022
US 12,729,229 B2Related patent
US 12,692,294 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results